Measles vaccination in the presence of maternal antibodies primes for a balanced humoral and cellular response to revaccination

Abstract

Early or low dose antigen exposure can prime the immune system for subsequent responses; the so-called “prime-boost” effect. In the context of a Sudanese measles vaccine trial, we assessed whether or not such early exposure could influence the response to revaccination. Children received either Connaught high titer vaccine (CN: n = 53; 10 4.7 pfu) or meningococcal A + C vaccine as a placebo (MEN: n = 58) at 5 months of age. At 9 months of age, all received standard titer Schwarz vaccine (SCH: 10 3.9 pfu). Neutralizing antibodies were measured before initial vaccination and at 9 months of age (plaque reduction neutralization assay (PRN)) and again at 5 years of age (syncytium inhibition assay (SIA)). Lymphoproliferative responses to measles virus (MV) antigens were evaluated at 5 years of age. Eleven of the 53 CN–SCH children (21%) had sub-protective neutralizing antibody titers prior to revaccination (log PRN 1.5 ± 0.03 versus 2.9 ± 0.07 in the remaining 42 children; P < 0.004). Maternal antibody titers at the time of initial vaccination in these 11 were high (PRN 2.44 ± 0.12 versus 1.9 ± 0.04; P < 0.0001). At 5 years of age, neutralizing antibodies were comparable in the 11 CN–SCH poor responders (log SIA 2.1 ± 0.09), the remaining CN–SCH children (2.2 ± 0.06) and the MEN–SCH group vaccinated only once at 9 months of age (2.25 ± 0.06). In contrast, 7/11 of the CN–SCH poor responders (64%) had stimulation indices (SI) > 3 in response to MV antigens at 5 years of age (SI 3.1 ± 0.6) compared with only 14% in the remaining children of the CN–SCH group (2.0 ± 0.3; P = 0.05) and 8% in the MEN–SCH group (1.4 ± 0.2; P < 0.0003). These data suggest that early measles vaccination in the presence of maternal antibodies can sometimes prime for a balanced humoral and cellular immune response to subsequent revaccination.